Based on the Regulus Therapeutics Inc stock forecast from 3 analysts, the average analyst target price for Regulus Therapeutics Inc is USD 8.75 over the next 12 months. Regulus Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Regulus Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Regulus Therapeutics Inc’s stock price was USD 1.27. Regulus Therapeutics Inc’s stock price has changed by +27.00% over the past week, -18.06% over the past month and -2.31% over the last year.
No recent analyst target price found for Regulus Therapeutics Inc
No recent average analyst rating found for Regulus Therapeutics Inc
Company Overview Regulus Therapeutics Inc
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. Read Less
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targ...Read More
Frequently Asked Questions About Regulus Therapeutics Inc (RGLS) Stock
Based on ratings from 3 analysts Regulus Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on RGLS's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for RGLS is USD 8.75 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 7.
Unfortunately we do not have enough data on RGLS's stock to indicate if its overvalued.
The last closing price of RGLS's stock was USD 1.27.
The most recent market capitalization for RGLS is USD 0.08B.
Based on targets from 3 analysts, the average taret price for RGLS is projected at USD 8.75 over the next 12 months.
This means that RGLS's stock price may go up by +588.98% over the next 12 months.
We can't find any ETFs which contains Regulus Therapeutics Inc's stock.
As per our most recent records Regulus Therapeutics Inc has 32 Employees.
Regulus Therapeutics Inc's registered address is 4224 Campus Point Court, San Diego, CA, United States, 92121.
You can get more information about it from Regulus Therapeutics Inc's website at https://www.regulusrx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Regulus Therapeutics Inc (RGLS) Stock
Based on ratings from 3 analysts Regulus Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on RGLS's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for RGLS is USD 8.75 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 7.
Unfortunately we do not have enough data on RGLS's stock to indicate if its overvalued.
The last closing price of RGLS's stock was USD 1.27.
The most recent market capitalization for RGLS is USD 0.08B.
Based on targets from 3 analysts, the average taret price for RGLS is projected at USD 8.75 over the next 12 months.
This means that RGLS's stock price may go up by +588.98% over the next 12 months.
We can't find any ETFs which contains Regulus Therapeutics Inc's stock.
As per our most recent records Regulus Therapeutics Inc has 32 Employees.
Regulus Therapeutics Inc's registered address is 4224 Campus Point Court, San Diego, CA, United States, 92121.
You can get more information about it from Regulus Therapeutics Inc's website at https://www.regulusrx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RGLS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
